BioCurex Updates Its Shareholders

July 2011
Biotech Financial Reports;Jul2011, Vol. 18 Issue 7, p5
Trade Publication
The article reports that chief executive officer (CEO) Ricardo Moro, of cancer diagnostics company BioCurex Inc., has sent a letter to update shareholders on the company's current and future programs. The letter provides information on programs including synthetic peptide for canine RECAF tests, innovative approaches to cancer detection, and molecular technology for diagnostics. Moro has emphasized that the company remains focused on blood tests for cancer detection in humans and in canines.


Related Articles

  • RECAF BLOOD TEST DETECTS 92% OF CERVICAL CANCERS.  // Worldwide Biotech;Jun2005, Vol. 17 Issue 6, p1 

    Reports on the completion of a study by BioCurex Inc. on the detection of cervical cancers with the use of the RECAF blood test, as of June 2005. Sensitivity of the traditional pap test in detecting high-grade lesions, according to the National Cancer Institute in the U.S.; Estimated market...

  • New Test for Ovarian Cancer.  // Medical Update;Feb2002, Vol. 27 Issue 8, p6 

    Reports on a study conducted by the U.S. National Cancer Institute that examined the use of an experimental blood test in the early detection of ovarian cancer.

  • BIOCUREX CANCER MONITORING DATA TO BE PRESENTED AT MEETING.  // Worldwide Biotech;Sep2010, Vol. 22 Issue 9, p6 

    The article reports on the International Society of Oncology and Biomarkers Congress Scientific Committee's acceptance of BioCurex Inc.'s presentation about the RECAF blood test potential to monitor cancer recurrence and treatment. BioCurex chief executive officer Ricardo Moro has also been...

  • Pinpoint problems. Munson, Marty; Yeykal, Teresa // Prevention;Sep95, Vol. 47 Issue 9, p58 

    Reports on a new blood test that determines the level of free prostate-specific antigens (PSA). Reduction in false positives; Clinical trials.

  • BEAT THE CANCER CLOCK. Worthington, Jane // Woman's Day (Australia Edition);11/29/2010, Vol. 62 Issue 48, p80 

    The article offers information on the Oncimmune early lung cancer detector test to detect lung cancer at an early stage.

  • BIOCUREX INCREASES CAPITALIZATION AND CHANGES NAME.  // Biotech Financial Reports;Dec2009, Vol. 16 Issue 12, p5 

    The article reports on the initiative of the Richmond, British Columbia-based Whispering Oaks International Inc. to change its company name and increase its capitalization. It notes that the proposals to change the company's name to BioCurex Inc. and increase its capitalization to 450,000,000...

  • Costs of bowel Ca screening to soar.  // Pulse;3/15/2007, Vol. 67 Issue 10, p15 

    The article focuses on a new British analysis which warns that bowel cancer screening will send demand for endoscopy by 69%. Figures based on the British colorectal cancer screening pilot suggest the resulting costs are expected to outstrip the allocated cash. About 1.9% of patients are likely...

  • COLORECTAL CANCER. Round, Alison; Weller, David // Pulse;3/22/2007, Vol. 67 Issue 11, p46 

    The article discusses the benefits of medical screening for early identification of colorectal cancer. The incidence of bowel cancer is highest in Great Britain but survival rates have improved due to early diagnosis and screening. Fecal occult blood testing is considered at the only method of...

  • Detecting colorectal cancer early.  // Consumer Reports on Health;Apr97, Vol. 9 Issue 4, p41 

    Suggests that annual fecal occult-blood testing can save lives by detecting colorectal cancer at an early curable stage. Method.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics